4,901 trials
Neoplasms With Mesothelin Expression · Epithelioid Mesothelioma · Cholangiocarcinoma, Extrahepatic
Primary: Maximum Tolerated Dose (MTD) of LMB-100 With Tofacitinib — 100 mcg/kg given days 4, 6, 8 every cycle
Lung Cancer
Primary: Confirmation of Tumor Targeting as Measured by the Number of Patients With Assessable Lesions Greater Than or Equal to 2 cm Measured by FDG-PET and SPECT Imaging. — 5; 5…
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) of Maribavir — 15.8; 17.4; 9.03; 26.3 Micrograms per milliliter (mcg/mL)
COVID-19
Primary: Occurrence of Solicited Local AE Signs and Symptoms 7 Days Following the Vaccination — 10; 12; 10; 2 Participants
Healthy Volunteers (Intended Indication: Chronic Kidney Disease)
Primary: Model Predicted Baseline-corrected and Placebo-corrected QT Interval Corrected for Heart Rate (HR) Using Fridericia's Formula (QTcF)(ΔΔQTcF) (Derived From…
HIV Infections
Primary: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) in Plasma Following Administration of Oral Dose of…
Malaria
Primary: Number of Participants With Local and Systemic Adverse Events in Year 1 — 2; 6; 4; 6 Participants
Solid Organ Malignancies · Adenoidcystic Carcinoma · Neuroendocrine Tumors
Primary: Number of Participants With Dose Limiting Toxicities (DLT) at Each Dose Level — 3; 3; 5; 3 Participants
Covid19
Primary: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 4; 4; 4; 0 Participants
Malaria
Primary: Analysis of 14C-Pyronaridine Total Radioactivity in Urine — 0.09; 0.16; 0.60; 0.71 % administered dose
Asthma
Primary: AUC0-t of Budesonide With and Without Charcoal Blockade — 1870; 1360; 1810; 1330 pg*h/mL — p=<0.001
Contraception
Primary: Number of Participants With Injection Site Reactions (ISRs) (Excluding Injection Site Pain) — 12; 6; 0; 8 Participants
Healthy Volunteers
Primary: Number of Participants With Treatment Emergent Adverse Events Per Group — 1; 0; 1; 1 Participants
Asthma
Primary: AUC0-last of Budesonide With and Without Charcoal Blockade — 1710; 1710; 1570; 1530 pg*h/mL — p=<0.001
Type 1 Diabetes Mellitus
Primary: Adverse Events — 5; 6; 10; 4 Number of AE